title: Localization of the stem cell markers LGR5 and Nanog in the normal and the cancerous human ovary and their inter-relationship.
abstract: LGR5 and Nanog were recently characterized as stem cell markers in various embryonic, adult and cancer stem cells. However, there are no data on their precise localization in the normal adult ovary, which may be important for the initial steps of development of ovarian cancer, the most lethal gynecological cancer. We analyzed by immunocytochemistry the precise localization of these markers in normal ovary (11 specimens, age range 43-76), in borderline specimens (12 specimens), and in serous ovarian cancer (12 specimens of stage II) which comprises the vast majority (80%) of all ovarian cancer. Surprisingly, we revealed that both Nanog and LGR5 are clearly localized in the epithelial cells of the normal ovary. However, in 5 of 12 ovaries there was no labeling at all, while in 3 ovaries staining of Nanog was more prominent with only weak labeling of LGR5. In addition, we found in 3 of 11 ovaries clear labeling in foci of both LGR5 and Nanog antibodies, with partial overlapping. Occasionally, we also found in the stroma foci labeled by either Nanog or LGR5 antibodies. In general, the stroma area of tissue sections labeled with LGR5 was much greater than that labeled with Nanog. In borderline tumors a significant portion of the specimens (7 of 12) was labeled exclusively with Nanog and not with LGR5. In ovarian carcinomas almost 100% of the cells were exclusively labeled only with Nanog (6 of 12 of the specimens) with no labeling of LGR5. These data may suggest the potential of ovaries from postmenopausal women, which express Nanog, to undergo transformation, since Nanog was shown to be oncogenic. We conclude that Nanog, which probably plays an important role in ovarian embryonic development, may be partially silenced in fertile and post-menopausal women, but is re-expressed in ovarian cancer, probably by epigenetic activation of Nanog gene expression. Expression of Nanog and LGR5 in normal ovaries and in borderline tumors may assist in the early detection and improved prognosis of ovarian cancer. Moreover, targeting of Nanog by inhibitory miRNA or other means may assist in treating this disease.
authors.affiliation: Department of Molecular Cell Biology, The Weizmann Institute of Science, 234, Herzl Street, Rehovot 76100, Israel. abraham.amsterdam@weizmann.ac.il
authors.forename: Abraham
authors.initials: A
authors.lastname: Amsterdam
authors.forename: Calanit
authors.initials: C
authors.lastname: Raanan
authors.forename: Letizia
authors.initials: L
authors.lastname: Schreiber
authors.forename: Ora
authors.initials: O
authors.lastname: Freyhan
authors.forename: Lea
authors.initials: L
authors.lastname: Schechtman
authors.forename: David
authors.initials: D
authors.lastname: Givol
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D018398:Homeodomain Proteins / Q000378:metabolism*; D006801:Humans; D008875:Middle Aged; D000071317:Nanog Homeobox Protein; D060787:Neoplasm Grading; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology*; D010053:Ovary / Q000378:metabolism / Q000473:pathology*; D017698:Postmenopause; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D018398:Homeodomain Proteins; C116884:LGR5 protein, human; C486780:NANOG protein, human; D000071317:Nanog Homeobox Protein; D043562:Receptors, G-Protein-Coupled